NBP
Price
$1.35
Change
+$0.01 (+0.75%)
Updated
Oct 2, 04:59 PM (EDT)
Capitalization
157.28M
41 days until earnings call
Intraday BUY SELL Signals
VSTM
Price
$7.71
Change
-$0.19 (-2.41%)
Updated
Oct 2, 04:59 PM (EDT)
Capitalization
703.68M
40 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

NBP vs VSTM

NBP vs VSTM Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
NBP vs. VSTM commentary
Oct 02, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NBP is a Hold and VSTM is a Hold.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS RATINGS
NBP vs VSTM: Fundamental Ratings
NBP
VSTM
OUTLOOK RATING
1..100
5078
VALUATION
overvalued / fair valued / undervalued
1..100
80
Overvalued
57
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
97100
PRICE GROWTH RATING
1..100
9036
P/E GROWTH RATING
1..100
98100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

VSTM's Valuation (57) in the Biotechnology industry is in the same range as NBP (80) in the null industry. This means that VSTM’s stock grew similarly to NBP’s over the last 12 months.

VSTM's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as NBP (100) in the null industry. This means that VSTM’s stock grew similarly to NBP’s over the last 12 months.

NBP's SMR Rating (97) in the null industry is in the same range as VSTM (100) in the Biotechnology industry. This means that NBP’s stock grew similarly to VSTM’s over the last 12 months.

VSTM's Price Growth Rating (36) in the Biotechnology industry is somewhat better than the same rating for NBP (90) in the null industry. This means that VSTM’s stock grew somewhat faster than NBP’s over the last 12 months.

NBP's P/E Growth Rating (98) in the null industry is in the same range as VSTM (100) in the Biotechnology industry. This means that NBP’s stock grew similarly to VSTM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NBPVSTM
RSI
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
84%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
68%
Bullish Trend 2 days ago
80%
Momentum
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 2 days ago
88%
MACD
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 2 days ago
82%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
85%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
84%
Advances
ODDS (%)
Bullish Trend 30 days ago
77%
Bullish Trend 3 days ago
82%
Declines
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 8 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
87%
COMPARISON
Comparison
Oct 02, 2026
Stock price -- (NBP: $1.34 vs. VSTM: $7.90)
Brand notoriety: NBP and VSTM are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NBP: 76% vs. VSTM: 82%
Market capitalization -- NBP: $157.28M vs. VSTM: $703.68M
NBP [@Biotechnology] is valued at $157.28M. VSTM’s [@Biotechnology] market capitalization is $703.68M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $133.74B. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NBP’s FA Score shows that 0 FA rating(s) are green while VSTM’s FA Score has 0 green FA rating(s).

  • NBP’s FA Score: 0 green, 5 red.
  • VSTM’s FA Score: 0 green, 5 red.
According to our system of comparison, VSTM is a better buy in the long-term than NBP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NBP’s TA Score shows that 4 TA indicator(s) are bullish while VSTM’s TA Score has 5 bullish TA indicator(s).

  • NBP’s TA Score: 4 bullish, 6 bearish.
  • VSTM’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, VSTM is a better buy in the short-term than NBP.

Price Growth

NBP (@Biotechnology) experienced а -7.59% price change this week, while VSTM (@Biotechnology) price change was +1.28% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -3.63%. For the same industry, the average monthly price growth was -14.35%, and the average quarterly price growth was -1.64%.

Reported Earning Dates

NBP is expected to report earnings on Nov 12, 2026.

VSTM is expected to report earnings on Nov 11, 2026.

Industries' Descriptions

@Biotechnology (-3.63% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
NBP
Daily Signal:
Gain/Loss:
VSTM
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
USL57.890.80
+1.41%
United States 12 Month Oil Fund LP (USL)
FNY99.220.39
+0.39%
First Trust Mid Cap Growth AlphaDEX Fund (FNY)
FSEC41.800.04
+0.10%
Fidelity Investment Grade Securitized ETF (FSEC)
MAXJ29.490.01
+0.04%
iShares Large Cap Max Buffer Jun ETF (MAXJ)
CRCD2.23-0.03
-1.33%
T-REX 2X Inverse CRCL Daily Target ETF (CRCD)

NBP and

Correlation & Price change

A.I.dvisor indicates that over the last year, NBP has been loosely correlated with VCYT. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if NBP jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NBP
1D Price
Change %
NBP100%
-1.83%
VCYT - NBP
43%
Loosely correlated
-4.02%
INDP - NBP
39%
Loosely correlated
-7.83%
VSTM - NBP
36%
Loosely correlated
-1.86%
IMNM - NBP
34%
Loosely correlated
-2.88%
FHTX - NBP
34%
Loosely correlated
-18.21%
More